The US Food and Drug Administration (FDA) has approved the first intranasal diuretic for heart, liver and kidney disease ...

Early findings suggest Aquadex as a potential solution to safely and effectively remove fluid volume for liver disease patients who don’t respond to diuretics MINNEAPOLIS, Feb. 06, 2024 (GLOBE ...

In a meta-analysis, researchers found no difference in all-cause mortality for intensive-care patients with fluid overload who were treated with loop diuretics, compared with those given a placebo or ...

MINNEAPOLIS, July 09, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NUWE) Nuwellis, Inc., a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to ...

MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the ...

EDEN PRAIRIE, Minn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced ...

Acetazolamide added to intravenous loop diuretics decreases congestion within three days in patients with acute decompensated heart failure, according to late breaking research presented in a Hot Line ...

NATIONAL HARBOR, Md.—Fluid overload in adult burn patients is associated with increased mortality, data presented at the National Kidney Foundation 2012 Spring Clinical Meetings suggest. Development ...

Nuwellis Inc (NASDAQ:NUWE) saw its stock decline by 10% after announcing it will discontinue its REVERSE-HF clinical trial, which was assessing the effectiveness of ultrafiltration versus intravenous ...

MINNEAPOLIS, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the ...